Results 71 to 80 of about 72,405 (280)
Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction.
Ying Zhou +3 more
doaj +1 more source
Infliximab in ulcerative colitis
Avi Levin, Oren ShiboletGastroenterology and Liver Units, Division of Medicine, Hadassah-Hebrew University Medical center, Jerusalem, IsraelAbstract: Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to ...
Avi Levin, Oren Shibolet
core
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar ...
C. Virga +6 more
core +1 more source
ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index ...
Phoebe L. Sault +3 more
wiley +1 more source
Cystoid Macular Edema: Possible Complication of Infliximab Therapy in Behçet’s Disease
Aim: Infliximab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, has been reported to be effective in refractory uveoretinitis in Behçet’s disease.
Junko Ikewaki +4 more
doaj +1 more source
Evaluation of the PK properties and biodistribution of pro-Infliximab and Infliximab.
The DBA/1J mice were intraperitoneally injected with 131I-labeled Infliximab (○) or 131I-labeled pro-Infliximab (□). The blood was collected at different time and the radioactivity was detected via the γ counter to measure the (A) PK properties of 131I ...
Kai-Wen Cheng (4583350) +13 more
core +1 more source
Infliximab in therapy of inflammatory bowels diseases [PDF]
Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim.
Rafał Filip +9 more
core +2 more sources
Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level.
Joo Hye Song +7 more
doaj +1 more source
Tumor necrosis factor α plays an important role in the pathogenesis of Crohn’s disease (CD). The effects of infliximab on gastrointestinal bleeding in CD have not yet been fully evaluated.
Manzurul Chowdhury +10 more
doaj +1 more source
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell +6 more
wiley +1 more source

